MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0000000000004161

Медицинская библиотека · AIDS (London, England) · 2025

Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virus.

Chalouni Mathieu, Van Santen Daniela K, Berenguer Juan, Jarrin Inmaculada, Miro José M, Klein Marina B, Young Jim, Torgersen Jessie, Rentsch Christopher T, Gill M John, Epstein Rachel L, Linas Benjamin, Zangerle Robert, Surial Bernard, Rauch Andri, Touloumi Giota, Papadopoulos Antonios, Wittkop Linda, Van Der Valk Marc, Boyd Anders, Monforte Antonella d'Arminio, Puoti Massimo, Logan Roger W, Rein Sophia M, Hernán Miguel A, Lodi Sara

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

People with HIV-hepatitis C virus (HCV) co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events and HCV transmission to others.

DESIGN

Target trial emulation with observational data collected in routine clinical practice from a collaboration of cohorts from Europe and North America.

METHODS

We included DAA-naive adults with HIV-HCV co-infection who achieved HIV virologic suppression (HIV RNA <50 copies/ml) after starting ART between 2013 and 2020. We estimated the probability of not initiating DAAs at 6 and 36 months after HIV virologic suppression and emulated a target trial of early (≤6 months after HIV virological suppression) versus delayed (>6 months) DAA initiation and the 36-month risk of liver-related events (liver decompensation or hepatocellular carcinoma).

RESULTS

Of 862 eligible individuals (median age 46 years; interquartile range 36-56), 14% were women, and 52% had a history of injection drug use. The 6-month and 36-month probabilities of not initiating DAA were 58% [95% confidence interval (CI): 55-61] and 24% (21-27), respectively. The 36-month risk of liver-related events was 1.1% (0.4-2.0) for early initiation and 1.7% (0.7-2.5) for delayed initiation; risk difference -0.5% (-1.2 to 0.4).

CONCLUSION

Almost one-quarter of people with HIV-HCV co-infection on ART had not initiated DAA 3 years after HIV virologic suppression. Because the 3-year risk of liver-related events was low, estimates of the impact of delayed DAA initiation were imprecise.

Для цитирования: Chalouni Mathieu, Van Santen Daniela K, Berenguer Juan, Jarrin Inmaculada, Miro José M, Klein Marina B, Young Jim, Torgersen Jessie, Rentsch Christopher T, Gill M John, Epstein Rachel L, Linas Benjamin, Zangerle Robert, Surial Bernard, Rauch Andri, Touloumi Giota, Papadopoulos Antonios, Wittkop Linda, Van Der Valk Marc, Boyd Anders, Monforte Antonella d'Arminio, Puoti Massimo, Logan Roger W, Rein Sophia M, Hernán Miguel A, Lodi Sara. Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virus.. AIDS (London, England). 2025. DOI: 10.1097/qad.0000000000004161.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.